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ABSTRACT
Infants with acute lymphoblastic leukemia (ALL) have a poor prognosis when treated with standard chemo-
therapy. A subset of these infants, particularly those with mixed-lineage leukemia (MLL) rearrangements, has
a high likelihood of relapse. Hematopoietic stem cell transplantation (HSCT) performed early in first remis-
sion may improve outcome. We present the results of 16 patients with infant ALL who were treated with
HSCT in first remission. Six patients were <6 months of age at diagnosis, 11 had an initial white blood cell
count of >50 000/L, and all patients with determinable cytogenetics had a high-risk karyotype [t(4:11)
abnormality or other MLL rearrangement]. All patients received 150 cGy of total body irradiation for 8 doses
(1200 cGy). Fifteen of 16 patients received etoposide at 1000 mg/m2 as a continuous infusion over 24 hours and
cyclophosphamide at 60 mg/kg/d for 3 days. Eight patients received HSCT from an HLA-identical sibling, and
8, from unrelated cord blood. Twelve (75%) patients remain long-term survivors (median follow-up, 4.7 years).
Two patients, 1 of whom had minimal residual disease at HSCT, died after relapse following HSCT. Two
patients died of transplant-related causes. The HSCT was well tolerated; 15 patients achieved neutrophil
engraftment at a median of 16 days. Acute and chronic graft-versus-host disease were minimal in these
patients. These results support the use of HSCT in the treatment of infant ALL, especially when used as
consolidation in first remission. The risk of relapse seems to be decreased with this approach. Further work is
being performed to determine the long-term effects from this therapy.
© 2005 American Society for Blood and Marrow Transplantation
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ANTRODUCTION
Hematopoietic stem cell transplantation (HSCT)
or infant acute lymphoblastic leukemia (ALL) re-
ains controversial [1], even though infant ALL
eems to be biologically distinct from other leukemias
nd is usually associated with a poor prognosis. Bio-
ogically, these leukemic cells often have 11q23 trans-
ocations or myeloid/lymphoid or mixed-lineage leu-
emia (MLL) rearrangements and lack the common
cute lymphoblastic leukemia antigen or CD10 anti-
en on their surface [2,3]. Among those with 11q23
ranslocations, it seems that infants with a 4:11 trans-
resented at the American Society of Hematology, San Diego, CA, De-
4ember 2004.
B&MTocation have an even worse prognosis and usually die
f progressive disease [4,5]. Other poor-prognostic
arkers in addition to the MLL gene and a lack of
D10 are age 6 months at diagnosis and a high
hite blood cell count at diagnosis [6]. Results of 59
nfants treated on the ALL-Berlin-Frankfurt-Munich
0 trial, in which all patients received intensive che-
otherapy and few received allogeneic HSCT in ﬁrst
omplete remission [CR1; only if a matched sibling
as available and if ultra-high-risk characteristics were
resent, such as a t(4:11) abnormality combined with
poor prednisone response], have been published [7].
he 6-year event-free survival (EFS) in this series was
0%. When combining data from ALL-BFM 86 and
LL-BFM 90, the 10-year EFS for 90 infants was
6% [8]. Furthermore, 23 infants with ALL treated
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1ith intensive therapy on the Dana-Farber Cancer
nstitute consortium protocols had an EFS of 54%. It
s interesting to note that of the 7 infants found to
ave a rearranged MLL gene, only 3 remained in CR1
9]. Clearly, infant ALL is a high-risk subgroup in
hich even more intense therapy needs to be studied.
Recent reports of myeloablative HSCT for infants
ith ALL have demonstrated EFS in the 64% to 76%
ange when HSCT is performed in CR1 [10-12].
urvival is compromised when HSCT is performed
eyond CR1 and is dismal when performed in relapse.
ur approach at Children’s Memorial Hospital has
een to perform HSCT in patients with infant ALL
arly in CR1 whenever possible. In 1999, we reported
small case series of these patients [13]. Given these
esults, we opted to continue our intensive approach
nd are now updating our results. We present the
esults, including transplant-related toxicities and sur-
ival, of 16 infants with ALL who underwent HSCT
n CR1.
ATIENTS AND METHODS
atients
Beginning in 1992, a standard cytoreduction reg-
men was used for transplantation in patients with
ematologic malignant disease regardless of stem cell
ource. Prophylaxis of infections and graft-versus-host
able 1. Characteristics and Outcome of HSCT in 16 Patients with In
Age
(mo) Sex
WBC
(109/L) Karyotype*
Prior
Chemotherapy† Type
7 M 61 High risk POG 9407 RBMT
4 M 29 High risk POG 9107 RBMT
6 M 400 High risk POG 9407 UCBT
7 F 4 Undeterm POG 9107 UCBT
15 F 546 High risk CCG 1961 UCBT
4 F 700 Undeterm POG 9407 UCBT
8 M 750 High risk POG 9407 UCBT
8 M 212 Undeterm POG 9407 RPBSCT
7 F 410 Undeterm POG 9407 RBMT
4 M 63 High risk POG 9107 RBMT
6 M 42 High risk POG 9107 RBMT
8 F 564 Undeterm POG 9407 UCBT
2 F 1000 High risk POG 9407 UCBT
8 M 37 High risk POG 9407 RBMT
9 M 360 High risk POG 9407 UCBT
8 M 36 High risk POG 9407 RBMT
BMT indicates related bone marrow transplant; UCBT, unrelat
transplant; TVC, TBI/etoposide/cyclophosphamide; MRD, mi
phosphamide/thiotepa; TAC, TBI/cytarabine/cyclophosphamid
Group; CCR, continuous complete remission; Rel, relapse; CSA
antithymocyte globulin.
High risk signiﬁes t(4:11) or MLL gene rearrangement. “Undeter
Most patients completed induction and intensiﬁcation (POG 940
Time from diagnosis to HSCT.
Death due to disease progression after single transplantation.
000isease (GVHD) was also comparable. Requirements
ncluded complete hematologic remission (histopa-
hologic analysis of bone marrow and cerebrospinal
uid [CSF]) within 2 weeks of HSCT and a Lansky
erformance status 90. Pretransplantation evalua-
ion of organs also needed to be satisfactory, with
ilirubin and creatinine 1.5 times the upper limit of
ormal and aspartate aminotransferase and alanine
minotransferase both 2.5 times the upper limit of
ormal. Also, the shortening fraction was required to
e 27% on echocardiogram and pulse oximetry had
o be 94% in room air with no evidence of dyspnea.
atched related donors were used whenever available;
therwise, infants received an unrelated cord blood
ransplant (CBT). All transplantation protocols were
pproved by the Children’s Memorial Hospital insti-
utional review board, and parents gave consent for
ransplantation and associated therapeutic procedures
nd interventions.
reatment
All patients were initially treated with intensive
ultidrug chemotherapy. Chemotherapy received be-
ore transplantation was composed of either Pediatric
ncology Group (POG) 9407 or POG 9107 in all but
patient, who was treated on the Children’s Cancer
tudy Group 1961 protocol (Table 1). Most patients
uickly went to HSCT after the induction and inten-
L
SCT
Conditioning
Regimen
GVHD
Prophylaxis Outcomeus HLA
Time
(mo)‡
6/6 7 TVC CSA/MTX CCR
6/6 14 TVC CSA/MTX CCR
5/6 4 TVC CSA/MTX/ATG TRM
5/6 10 TVCT CSA/MTX/ATG CCR
6/6 8 TVC CSA/MTX/ATG CCR
4/6 4 TVCT CSA/MTX/ATG TRM
5/6 4 TAC CSA/MTX/ATG CCR
6/6 3 TVC CSA/MTX CCR
6/6 3 TVC CSA/MTX CCR
6/6 3 TVC CSA/MTX CCR
6/6 2 TVC CSA/MTX Rel§
4/6 4 TVC CSA/MTX/ATG CCR
RD 4/6 5 TVC CSA/MTX/ATG Rel§
6/6 3 TVC CSA/MTX CCR
4/6 5 TVC CSA/MTX/ATG CCR
6/6 4 TVC CSA/MTX Rel
d blood transplant; RPBSCT, related peripheral blood stem cell
residual disease at transplantation; TVCT, TBI/etoposide/cyclo-
M, transplant-related mortality; CCG, Children’s Cancer Study
porin A; MTX, methotrexate; WBC, white blood cell count; ATG,
resents an undeterminable karyotype.
duction and a partial ﬁrst cycle of postinduction (POG 9107).fant AL
H
Stat
CR1
CR1
CR1
CR1
CR1
CR1
CR1
CR1
CR1
CR1
CR1
CR1
CR1/M
CR1
CR1
CR1
ed cor
nimum
e; TR
, cyclos
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HSCT for Infant ALL
Biﬁcation phases of chemotherapy and documentation
f morphologic CR. Two patients, 1 on POG 9407
nd 1 on POG 9107, continued on their protocol
hrough consolidation before they received HSCT.
All patients received 150 cGy of total body irradi-
tion (TBI) for 8 doses (total, 1200 cGy) on days 9,
8, 7, and 6. Fifteen of 16 patients received eto-
oside 1000 mg/m2 as a continuous infusion on days
5 and 4 and cyclophosphamide 60 mg/kg/d on
ays 4, 3, and 2, with mesna uroprophylaxis.
ne patient, enrolled in a POG protocol, received
ytarabine 100 mg/kg per dose every 12 hours for 4
ays instead of etoposide, and the cyclophosphamide
osing was different (45 mg/kg/d on days7 and6).
rom 1996 to 1999, unrelated CBT recipients (n  2)
lso received 1 dose of thiotepa 5 mg/kg on day 5.
atients with negative CSF cytology at all times be-
ore HSCT received triple intrathecal therapy (metho-
rexate, hydrocortisone, and cytarabine) monthly for 6
onths after HSCT if 1 year of age. Patients with a
istory of positive CSF cytology at any time before
SCT received an additional 1200-cGy cranial boost
efore HSCT. All boys received an additional 400-
Gy boost to the testes.
HLA typing was performed by serologic methods
or class I antigens with conﬁrmation of class II antigens
y molecular analysis for all recipients and matched-
ibling donors. Hematopoietic stem cells were not
-cell depleted or purged. Acute GVHD prophylaxis
or matched related transplants consisted of cyclo-
porine (CSA) 1.5 mg/kg per dose intravenously every
2 hours and methotrexate on days 1 (15 mg/m2), 3
10 mg/m2), and 6 (10 mg/m2). CSA was changed to
he oral route once the patient was tolerating oral
ntake. Unrelated CBT recipients received continu-
us-infusion CSA (5 mg/kg/d), which was changed to
he oral route when they tolerated oral intake; short-
ourse methotrexate, as described previously; and
quine antithymocyte globulin (Upjohn, Columbus,
H) 20 mg/kg (premedicated with methylpred-
isolone 2 mg/kg per dose) on days 1, 3, 5, and 7.
All patients were cared for in positive-pressure
aminar ﬂow rooms. Additional supportive care in-
luded prophylactic ﬂuconazole 3 to 5 mg/kg/d and oral
cyclovir 250 mg/m2 twice daily through day 180.
ntravenous immunoglobulin (250 mg/kg) or cyto-
egalovirus immune globulin (100 mg/kg; in the case
f a cytomegalovirus-positive patient or donor) was
dministered weekly until day100 and then monthly
ntil 6 months after HSCT. Pentamidine (4 mg/kg
ntravenously) was given monthly for Pneumocystis ca-
inii prophylaxis. Beginning in 1995, all patients re-
eived granulocyte colony-stimulating factor 5 to 10
g/kg starting at day 7. Broad-spectrum antibiotics
ere started empirically for fever and neutropenia. In
eneral, for clinical grade II or greater acute GVHD,
ocumented histologically, initial treatment was with 
B&MTethylprednisolone 2 mg/kg/d. Progression or no re-
ponse after 1 week usually led to additional immuno-
uppressive therapy with agents such as antithymocyte
lobulin, inﬂiximab, or daclizumab, or switching cal-
ineurin inhibitor. Acute GVHD was graded at least
eekly according to the Keystone criteria, and chronic
VHD was deﬁned as limited or extensive [14,15].
Engraftment of neutrophils was deﬁned as achieve-
ent of a peripheral neutrophil count 500/L for 3
onsecutive days. Engraftment of platelets was deﬁned
s a platelet count 20 000/L without transfusions
or at least the preceding 7 days. Patients were not
onsidered eligible for platelet engraftment if they
ied and did not have an unsupported platelet count
20 000/L before day 180. Donor engraftment was
etermined by polymerase chain reaction assay of
enomic DNA for variable number tandem repeat
olymorphisms [16] after the year 2000 and by restric-
ion fragment length polymorphism before then.
tatistical Methods
Patient characteristics, including transplant- and
isease-related variables, were described by using me-
ians and frequencies for continuous and categorical
ariables, respectively. The duration for transplant-
elated outcomes used July 1, 2005, as the date of last
ollow-up, and, hence, observations are right-cen-
ored. Kaplan-Meier analysis was used to assess re-
apse, overall survival, and EFS and to obtain esti-
ates of median survival at 1 and 3 years. Days to
eutrophil and platelet recovery are described by us-
ng medians with ranges. Median neutrophil recovery
as calculated for patients whose neutrophils recov-
red by day 60, and median platelet recovery was
alculated for patients whose platelets recovered by
ay 180. Incidences of acute and chronic GVHD were
alculated with conﬁdence intervals (CIs). The data
ere complete, and 5% was used as the level of sig-
iﬁcance. Statistical analyses were conducted with
tata 6.0 (StataCorp LP, College Station, TX).
ESULTS
atient Characteristics at Diagnosis
nd Transplantation
Tables 1 and 2 list the patient characteristics at
iagnosis and at transplantation. The median age at
ransplantation was 11.5 months (range, 6-22 months),
nd the median time from diagnosis to transplantation
as 4 months (range, 2-14 months). The median age
t diagnosis for this group of patients was 7 months
range, 2-15 months). All patients except 1 were 1
ear of age at diagnosis. The 15-month-old was in-
luded in this series given the presence of MLL gene
earrangement and a white blood cell count
500 000/L at diagnosis, which suggested that this
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1hild’s ALL had infant-type biology. Six patients
38%) were 6 months of age at diagnosis, 11 (69%)
ad an initial white blood cell count50 000/L, and
ll 11 patients with determinable cytogenetics had a
igh-risk karyotype [a t(4:11) abnormality or other
LL gene rearrangement]. Twelve (75%) patients
ere negative for CD10 antigen expression on their
eukemic blasts. Central nervous system disease was
resent in 4 (25%) patients. At transplantation, all
atients were in morphologic CR; however, 1 patient
ad evidence of persistent minimal residual disease
iven the presence of a karyotype abnormality.
The transplantation regimen included TBI, cyclo-
hosphamide, and etoposide in all patients except 1,
ho received cytosine arabinoside instead of etoposide
as part of a POG protocol). Donors were 8 HLA-
dentical siblings (7 bone marrow and 1 peripheral
lood stem cells) and 8 unrelated cord blood donors,
f which 4 were 4/6 HLA matched, 3 were 5/6 HLA
atched, and 1 was a 6/6 HLA match. The median
ell dose infused was 3.6  108 total nucleated cells
er kilogram (range, 2.6-4.8) for HLA-identical sib-
ings and 1.2  108 total nucleated cells per kilogram
range, 0.9-2.4) for unrelated CBT. All recipients and
onors were cytomegalovirus seronegative.
ngraftment
Fifteen of the 16 patients achieved a neutrophil
able 2. Presenting Characteristics and Initial Outcome in 16
atients with Infant ALL
Feature Data
ex, n (%)
Male 10 (63%)
Female 6 (37%)
D10 antigen, n (%)
Positive 3 (19%)
Negative 12 (75%)
Unknown 1 (6%)
ge at diagnosis (mo)
Median 7.2
Range 2-15
BC (109/L)
Median 286
Range 4.3-1000
xtramedullary disease at diagnosis, n (%)
CNS 4 (25%)
None 12 (75%)
aryotype, n (%)
t(4:11) 10 (62%)
Other MLL 1 (6%)
Undeterminable 5 (32%)
utcome, n (%)
Relapse (death) 2 (13%)
Relapse (alive in CR2) 1 (6%)
TRM 2 (13%)
CCR 11 (69%)
BC indicates white blood cell count; CNS, central nervous sys-
tem; TRM, transplant-related mortality; CCR, continuous com-
plete remission since transplantation.ount 0.5  108/L. The median time was 16 days m
002range, 11-25 days). Fourteen patients achieved an
nsupported platelet count 20 000/L at a median
f 36 days (range, 12-82 days). The patients who did
ot achieve neutrophil engraftment and platelet en-
raftment received unrelated CBT. Patients who re-
eived transplants from a matched sibling donor
chieved neutrophil engraftment an average of 6 days
aster (P .01) and platelet engraftment an average of
0 days faster (P  .006) than those who received
ransplants from an unrelated cord blood source.
here were no cases of graft rejection.
VHD and Transplant-Related Toxicities
Three (19%; 95% CI, 4%-45%) of 16 patients
eveloped grade II or III acute GVHD; there were no
ases of grade IV acute GVHD (Table 3). These 3
atients all received unrelated CBT. Of 12 evaluable
atients, 4 (33%; 95% CI, 9%-65%) developed
hronic GVHD. Three cases were limited (from an
nrelated CBT), and 1 was extensive (from a matched
ibling). There were no cases of veno-occlusive disease
nd no cases of fungal infection. Eight patients had
ocumented bacteremia with fever, but there were no
ases of death due to sepsis. All patients experienced
ucositis, which resolved. Long-term sequelae are
urrently being assessed and will be the subject of a
uture article. Brieﬂy, no surviving patient has any
rohibitive complications. The main observation has
een growth impairment.
onrelapse Mortality, Relapse, and Survival
Two patients (12%; 95% CI, 1%-38%) died of
onrelapse causes on days 36 and 42. Both of these
atients received unrelated CBT. Causes of death
ere pulmonary hemorrhage in 1 and respiratory dis-
ress syndrome with parainﬂuenza infection in the
ther.
Two of 14 evaluable patients relapsed at 48 and
29 days and died of progressive disease. One had
eceived bone marrow from a matched sibling, and 1
ad received unrelated CBT. The patient who re-
apsed at day 48 was the 1 patient with a persistent
ytogenetic abnormality at transplantation. Finally, 1
atient who had received a matched-sibling transplant
elapsed in the testes and bone marrow 210 days after
ransplantation. He is currently in remission after sal-
age induction chemotherapy and will undergo a re-
uced-intensity transplant.
To summarize, 12 (75%; 95% CI, 47%-92%) of
6 patients survive with a median follow-up of 4.7
ears (range, 0.6-12.6 years). The estimated probability
f EFS at 1 year is 64% (95% CI, 40%-88%). The
stimated overall survival at 1 and 3 years is 75% (95%
I, 47%-92%) (Figure 1). Given the small numbers, no
eaningful comparison can be made of survival between
atched sibling and unrelated CBT.
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HSCT for Infant ALL
BISCUSSION
Controversy remains regarding the most appro-
riate therapy for infants with ALL. The results of
atients treated with chemotherapy alone demon-
trate survival in the 20% to 40% range, with partic-
larly dismal survival in patients with MLL gene re-
rrangements, CD10 negativity, or both [17-20]. We
escribe excellent outcomes with allogeneic HSCT
or infant ALL when it is performed as consolidation
herapy early and in CR1. Of 16 infants treated with
his approach, 12 remain long-term survivors.
Stem cell transplantation may be an attractive op-
ion for improving EFS in infants with ALL. In addi-
ion to delivery of high doses of chemotherapy, radio-
herapy, or both, there is a graft-versus-leukemia
ffect associated with transplantation that may play a
ole in infant ALL. However, some of the concerns
ith HSCT are morbidity and mortality from the
reparative regimen and a potential increase in late
ffects given the delivery of high-dose radiation, che-
otherapy, or both at such a young age. Given the
arity of infant ALL, all reports of HSCT for this
isease have a small number as their main limitation.
Marco et al. [10] performed HSCT in 26 patients
ith either lymphoblastic or myeloid infant leukemia.
f the 10 ALL patients, 6 received autologous and 4
llogeneic HSCT. The conditioning regimen for all
atients was busulfan based and did not include radi-
tion. Within the ALL patients, there was a 5-year
FS of 56%. Improved survival was noted in patients
ho received HSCT within 4 months of achieving
R1. Key differences as compared with our study are
hat more than half of the patients received autologous
ells and that the preparative regimen did not contain
BI. Possible concerns with using autologous cells
re, obviously, the reinfusion of cells with minimal
esidual disease and the lack of a graft-versus-leukemia
able 3. Toxicities Associated with HSCT
Variable n
auses of death (n  4)
Relapse 2
Transplant-related mortality 2
Pulmonary hemorrhage 1
Parainfluenza (RDS) 1
omplications other than TRMs
Acute GVHD 10
Grade I 7
Grades II-III 3
Chronic GVHD 4
Limited 3
Extensive 1
Mucositis 16
Fever and neutropenia 15
Documented bacteremia 5
DS indicates respiratory distress syndrome; GVHD, graft-versus-
host disease.ffect from an allogeneic transplant. t
B&MTKosaka et al. [11] recently reported their results of
1 infant ALL patients with MLL positivity and the
bsence of CD10 expression. Thirty-eight patients
nderwent allogeneic HSCT with a 3-year EFS of
4%. Survival was clearly better for those who under-
ent transplantation in CR1 (64% for 29 patients) as
pposed to CR2 or greater (22% for 9 patients). Most
atients in this report received unrelated cord blood as
heir source of stem cells. The conditioning regimen
as not uniform (either TBI based or busulfan based),
nd GVHD prophylaxis also varied. Sanders et al. [12]
ecently reported on 40 infants, most with MLL gene
earrangements, who received allogeneic HSCT.
ost patients received a TBI/cyclophosphamide reg-
men. The main predictor of survival was phase of
isease. EFS was 76% for 17 patients in CR1, 45% for
in CR2, and 8% for 16 in relapse. Both of these
eports suggest that consolidation with transplanta-
ion soon after achievement of CR1 improves survival
n ALL.
Since the inception of the transplantation program
n 1992, it has been the philosophy at Children’s
emorial Hospital to submit all patients with infant
LL to HSCT. Selection bias is possible in that some
atients may have died before getting to HSCT, al-
hough the intent was that all patients with infant ALL
ould receive HSCT. Our patients represent a very
igh-risk group (Table 2), consistent with the publi-
ations described previously. Most notably, all 11
valuable patients had an MLL gene rearrangement,
hich seems to be the most important poor-risk factor
n these patients.
Our report represents one of the largest cohorts of
nfants with ALL who have undergone HSCT in CR1
y using a uniform transplantation regimen. Our
reatment protocol is different from and more inten-
ive than others [11,12] in that in addition to TBI, the
ose of cyclophosphamide is 180 mg/kg (instead of
20 mg/kg), and the regimen also includes etoposide.
igure 1. Overall survival (OS) in 16 infants with acute lympho-
lastic leukemia who underwent hematopoietic stem cell transplan-
ation in morphologic complete remission.
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1he median time from diagnosis to transplantation
as 4 months, which is similar that reported by Sand-
rs et al. [12] and Kosaka et al. [11]. Although we are
nable to analyze outcome according to time from
iagnosis to transplantation, our results do suggest,
specially when viewed in the context of the 2 other
tudies, that early transplantation in CR1 yields excel-
ent survival in these high-risk patients. Of 16 patients,
nly 2 relapsed, well within 1 year from transplanta-
ion. It is worthwhile to note that although all patients
ere in a morphologic remission, 1 had deﬁnite evi-
ence of minimal residual disease, given the presence
f abnormal cytogenetics at transplantation. One may
onclude that this patient had chemorefractory dis-
ase, and this further underscores the importance of a
rue remission for transplantation to have a positive
ffect.
In our experience, engraftment was good, and tox-
cities were low and very manageable. The excellent
ngraftment, despite our use of unrelated cord blood
n many patients, may be due to the immaturity of the
nfants’ immune systems and the large number of cells
er kilogram achieved given their low weight. Further-
ore, the rates of severe acute GVHD and extensive
hronic GVHD are very low, whichmay be due not only
o the immature immune system, but also to the fact that
hese patients were not heavily pretreated, which can
e associated with increased GVHD. The transplant-
elated mortality of 12% is also quite favorable, once
gain highlighting the importance of a good perfor-
ance before transplantation. Other than these 2
eaths, there were no major complications, such as
ungal infection or veno-occlusive disease. The fact
hat there were no late deaths suggests good immune
econstitution and minimal chronic GVHD.
Clearly, concern exists regarding late sequelae
ith TBI in infants. Growth impairment is more pro-
ounced in infants who have undergone HSCT with
BI as opposed to chemotherapy-only regimens [21].
eung et al. [22] recently analyzed a small group of
nfant ALL survivors and found that if they had been
reated with transplantation and radiation, as opposed
o chemotherapy only, there was an increased rate of
ate sequelae. The main late effects his group found
ere growth impairment, learning impairment, hypo-
hyroidism, and delay of pubertal development. In
ddition to these late effects, Sanders and colleagues’
12] recent publication also highlights osteopenia and
ataracts. It is interesting to note that there were no
evere neurocognitive delays in 16 patients who had
esting after HSCT. This is in clear contrast to the
igh rate of neurocognitive delays reported by Leung
t al. [22]. Our group is currently in the process of
nalizing neuropsychiatric testing in the surviving in-
ants, and these data will form part of a follow-up
rticle documenting late effects in these infants.The risks and beneﬁts, therefore, need to be 1
004learly weighed before infants with ALL are submit-
ed to HSCT. From our experience and that of a few
thers, it does seem that infants with very-high-risk
eukemia, mainly those with MLL gene rearrange-
ents, beneﬁt from high-intensity allogeneic HSCT.
welve (75%) of our 16 patients are long-term survi-
ors. The beneﬁt seems to be most evident when
SCT is performed in CR1, within months from
iagnosis. Certainly work remains to be performed to
etermine whether the bulk of the effect is from the
igh-dose therapy or from an allogeneic (graft-versus-
eukemia) effect. If an allogeneic effect does seem to
lay a role in this setting, then some of the long-term
oxicities could be avoided by using reduced-intensity
onditioning. This area deserves future investigation.
EFERENCES
1. Pui CH, Chessells JM, Camitta B, et al. Clinical heterogeneity
in childhood acute lymphoblastic leukemia with 11q23 rear-
rangements. Leukemia. 2003;17:700-706.
2. Pui CH, Kane JR, Crist WM. Biology and treatment of infant
leukemias. Leukemia. 1995;9:762-769.
3. Ishii E, Okamura J, Tsuchida M, et al. Infant leukemia in Japan:
clinical and biological analysis of 48 cases. Med Pediatr Oncol.
1991;19:28-32.
4. Reaman GH, Steinherz PG, Gaynon PS, et al. Improved sur-
vival of infants less than 1 year of age with acute lymphoblastic
leukemia treated with intensive multiagent chemotherapy. Can-
cer Treat Rep. 1987;71:1033-1038.
5. Ferster A, Bertrand Y, Benoit Y, et al. Improved survival for
acute lymphoblastic leukaemia in infancy: the experience of
EORTC-Childhood Leukaemia Cooperative Group. Br J
Haematol. 1994;86:284-290.
6. Reaman G, Zeltzer P, Bleyer WA, et al. Acute lymphoblastic
leukemia in infants less than one year of age: a cumulative
experience of the Children’s Cancer Study Group. J Clin Oncol.
1985;3:1513-1521.
7. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome
in childhood acute lymphoblastic leukemia despite reduced use
of anthracyclines and cranial radiotherapy: results of trial ALL-
BFM 90. German-Austrian-Swiss ALL-BFM Study Group.
Blood. 2000;95:3310-3322.
8. Pui CH, Schrappe M, Ribeiro RC, et al. Childhood and ado-
lescent lymphoid and myeloid leukemia. Hematology (Am Soc
Hematol Educ Program ). 2004;118-145.
9. Silverman LB, McLean TW, Gelber RD, et al. Intensiﬁed
therapy for infants with acute lymphoblastic leukemia: results
from the Dana-Farber Cancer Institute Consortium. Cancer.
1997;80:2285-2295.
0. Marco F, Bureo E, Ortega JJ, et al. High survival rate in infant
acute leukemia treated with early high-dose chemotherapy and
stem-cell support. Groupo Espanol de Trasplante de Medula
Osea en Ninos. J Clin Oncol. 2000;18:3256-3261.
1. Kosaka Y, Koh K, Kinukawa N, et al. Infant acute lymphoblas-
tic leukemia with MLL gene rearrangements: outcome follow-
ing intensive chemotherapy and hematopoietic stem cell trans-
plantation. Blood. 2004;104:3527-3534.2. Sanders JE, Im HJ, Hoffmeister PA, et al. Allogeneic hemato-
11
1
1
1
1
1
2
2
2
HSCT for Infant ALL
Bpoietic cell transplantation for infants with acute lymphoblastic
leukemia. Blood. 2005;105:3749-3756.
3. Pirich L, Haut P, Morgan E, et al. Total body irradiation,
cyclophosphamide, and etoposide with stem cell transplant as
treatment for infants with acute lymphocytic leukemia. Med
Pediatr Oncol. 1999;32:1-6.
4. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-
versus-host disease in 52 patients: adverse natural course and
successful treatment with combination immunosuppression.
Blood. 1981;57:267-276.
5. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus
Conference on Acute GVHD Grading. Bone Marrow Trans-
plant. 1995;15:825-828.
6. Ugozzoli L, Yam P, Petz LD, et al. Ampliﬁcation by the
polymerase chain reaction of hypervariable regions of the hu-
man genome for evaluation of chimerism after bone marrow
transplantation. Blood. 1991;77:1607-1615.
7. Reaman GH, Sposto R, Sensel MG, et al. Treatment outcome
and prognostic factors for infants with acute lymphoblastic
B&MTleukemia treated on two consecutive trials of the Children’s
Cancer Group. J Clin Oncol. 1999;17:445-455.
8. Frankel LS, Ochs J, Shuster JJ, et al. Therapeutic trial for infant
acute lymphoblastic leukemia: the Pediatric Oncology Group
experience (POG 8493). J Pediatr Hematol Oncol. 1997;19:35-
42.
9. Chessells JM, Harrison CJ, Watson SL, et al. Treatment of
infants with lymphoblastic leukaemia: results of the UK Infant
Protocols 1987-1999. Br J Haematol. 2002;117:306-314.
0. Borkhardt A, Wuchter C, Viehmann S, et al. Infant acute
lymphoblastic leukemia—combined cytogenetic, immunophe-
notypical and molecular analysis of 77 cases. Leukemia. 2002;
16:1685-1690.
1. Isoyama K, Eguchi M, Hibi S, et al. Risk-directed treatment of
infant acute lymphoblastic leukaemia based on early assessment
of MLL gene status: results of the Japan Infant Leukaemia
Study (MLL96). Br J Haematol. 2002;118:999-1010.
2. Leung W, Hudson M, Zhu Y, et al. Late effects in survivors of
infant leukemia. Leukemia. 2000;14:1185-1190.
1005
